BiotechTube
Cyrano Therapeutics

Cyrano Therapeutics

Cambridge, United States· Est.
cyranotherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Cyrano Therapeutics is pioneering a regenerative therapy for post-viral smell loss (hyposmia), a significant and growing unmet medical need exacerbated by the COVID-19 pandemic. The company's lead asset, CYR-064, recently reported positive topline safety and efficacy results from a Phase 2 trial (FLAVOR), supporting advancement into Phase 3 development planned for the second half of 2026. As a private, pre-revenue company, Cyrano is positioning itself to address a market affecting millions of patients in the U.S. alone, with no currently approved pharmaceutical treatments available. Its progress makes it a notable player in the emerging field of sensory restoration.

Olfactory DysfunctionSensory Disorders

Technology Platform

Proprietary regenerative small molecule (CYR-064) delivered via intranasal soft-mist spray designed to repair or regenerate the olfactory epithelium.

Funding History

2
Total raised:$20M
Series A$15M
Seed$5M

Opportunities

The COVID-19 pandemic created a massive, new, and motivated patient population with persistent smell loss, representing a greenfield market with no approved pharmacotherapies.
Successful development could establish a first-in-class treatment with potential for expansion into related indications like taste loss or smell impairment from trauma or neurodegeneration.

Risk Factors

The company faces significant clinical risk as its lead candidate must succeed in a larger, pivotal Phase 3 trial.
Regulatory and reimbursement pathways for a first-in-class therapy in this indication are not yet established.
Furthermore, market adoption requires educating physicians and patients about a new treatment paradigm.

Competitive Landscape

There are currently no FDA-approved pharmaceutical treatments for smell loss, positioning Cyrano as a potential first-mover. Competition primarily consists of supportive care methods like olfactory training and off-label use of steroids. Other biotech or pharma companies may enter the space given the increased market attention, but no direct clinical-stage competitors are currently highlighted.

More companies in Small Molecule Drugs →More companies in United States →